Postradiotherapy prostate biopsies: What do they really mean? Results for 498 patients

International Journal of Radiation Oncology Biology Physics

Volumn 48, Issue 2, 2000, Pages 355-367

  Crook, Juanita ^a,f   Malone, Shawn ^c   Perry, Gad ^c   Bahadur, Yasir ^d   Robertson, Susan ^e   Abdolell, Mohamed ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c OTTAWA REGIONAL CANCER CENTRE   (Canada)

^d KING ABDUL AZIZ UNIVERSITY HOSPITAL   (Saudi Arabia)

^e UNIVERSITY OF OTTAWA   (Canada)

^f PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Outcome prediction; Postradiation biopsies; Prostate cancer; Radiotherapy

Indexed keywords

HORMONE;

ADULT; AGED; ARTICLE; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC ERROR; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; RADIATION RESPONSE; TREATMENT FAILURE; TREATMENT OUTCOME; TUMOR REGRESSION;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BIOPSY; CAUSE OF DEATH; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; HORMONES; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROLIFERATING CELL NUCLEAR ANTIGEN; PROSPECTIVE STUDIES; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 0033832224     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(00)00637-4     Document Type: Article

References (41)

1. Zeitman A.L., Tibbs M.K., Dallow K.C., Smith C.T., Althausen A.F., Zlotecki R.A., Shipley W.U. Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate. Radiother Oncol. 40:1996;159-162.
2. Lee W., Hanlon A., Hanks G. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer The relationship between nadir level and disease-free survival . J Urol. 156:1996;450-453.
3. Critz F.A., Levinson A.K., Williams H., Holladay D.A. Prostate-specific antigen nadir The optimum level after irradiation for prostate cancer . J Clin Oncol. 14:1996;2893-2900.
4. Kuban D.A., El-Mahdi A.M., Schellhammer P.F. PSA for outcome prediction and posttreatment evaluation following radiation for prostate cancer Do we know how to use it? Semin Radiat Oncol. 8:1998;72-80.
5. American Society of Therapeutic Radiology and Oncology consensus statement Guidelines for PSA following radiation therapy . Int J Radiat Oncol Biol Phys. 37:1997;1035-1041.
6. Crook J.M., Choan E.G., Perry G.A., Robertson A., Esche B.A. Serum prostate-specific antigen profile following radiotherapy for prostate cancer Implications for patterns of failure and definition of cure . Urology. 51:1998;566-572.
7. Mostofi F.K., Sesterhenn I.A., Davis C.J. Jr. A pathologist's view of prostatic carcinoma. Cancer. 71:1993;906-932.
8. Hermanek P, Sobin LH, eds. International Union Against Cancer. TNM classification of malignant tumours. 4th ed, 2nd rev. Berlin: Springer-Verlag; 1992.
9. Crook J.M., Perry G.A., Robertson S., Esche B.A. Routine prostate biopsies following radiotherapy for prostate cancer Results for 226 patients . Urology. 45:1995;624-632.
10. Brawer M.K., Nagle R.B., Pitts W., Freiha F., Gamble S.L. Keratin as an aid to the diagnosis of persistent adenocarcinoma in irradiated human prostates. Cancer. 63:1989;454-460.
11. Crook J.M., Bahadur Y.A., Robertson S.J., Perry G.A., Esche B.A. Evaluation of radiation effect, tumor differentiation, and prostate specific antigen staining in sequential prostate biopsies after external beam radiotherapy for patients with prostate carcinoma. Cancer. 79:1997;81-89.
12. Allison P.D. Survival analysis using the SAS system A practical guide . 1995;SAS Institute, Cary, NC.
13. Becker R.A., Chambers J.M., Wilms A.R. The New S Language. 1988;Wadsworth, Pacific Grove, CA.
14. Kaplan E.L., Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc. 53:1958;457-481.
15. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 50:1966;163-170.
16. Cox P.D. Regression models and life tables. J Royal Stat Soc. B34:1972;187-202.
17. Babaian R.J., Kojima M., Saitoh M., Ayala A. Detection of residual prostate cancer after external radiotherapy. Cancer. 75:1995;2153-2158.
18. Crook J., Robertson S., Collin G., Zaleski V., Esche B. Clinical relevance of trans-rectal ultrasound, biopsy, and serum prostate specific antigen following external beam radiotherapy for carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 27:1993;31-37.
19. Kuban D.A., El-Mahdi A.M., Schellhammer P.F. The significance of post- irradiation prostate biopsy with long-term follow-up. Int J Radiat Oncol Biol Phys. 24:1992;409-414.
20. Miller E.B., Ladaga L.E., El-Mahdi A.M., Schellhammer P.F. Reevaluation of prostate biopsy after definitive radiation therapy. Urology. 41:1993;311-316.
21. Scardino P.T. The prognostic significance of biopsies after radiotherapy for prostatic cancer. Sem Urol. 1:1983;243-252.
22. Scardino P.T., Wheeler T.M. Local control of prostate cancer with radiotherapy Frequency and prognostic significance of positive results of post-irradiation prostate biopsy . NCI Monogr. 7:1988;95-103.
23. 125iodine implant or external beam radiation therapy. J Urol. 137:1987;897-901.
24. Hanks G.E., Lee W.R., Hanlon A.L., Hunt M., Kaplan E., Epstein B.E., Movsas B., Schultheiss T.E. Conformal technique dose escalation for prostate cancer Biochemical evidence of improved cancer control with higher doses in patients with pretreatment prostate-specific antigen ≥ 10 ng/mL . Int J Radiat Oncol Biol Phys. 35:1996;861-868.
25. Zelefsky M.J., Leibel S.A., Gaudin P.B., Kutcher G.J., Fleshner N.E., Venkatramen E.S., Reuter V.E., Fair W.R., Ling C.C., Fuks Z. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 41:1998;491-500.
26. Pollack A., Zagars K. External beam radiotherapy dose response of prostate cancer. Int J Radiat Oncol Biol Phys. 39:1997;1011-1018.
27. Kupelian P., Katcher J., Levin H., Zippe C., Suh J., Muchlis R., Klin E. External beam radiotherapy vs. radical prostatectomy for clinical Stage T1-2 prostate cancer Therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores . Ca J Sci Am. 3:1997;78-87.
28. ASTRO consensus statements on radiation therapy of prostate cancer Guidelines for prostate rebiopsy after radiation and for radiation therapy with rising prostate-specific antigen levels after radical prostatectomy . J Clin Oncol. 17:1999;1155-1163.
29. Goldstein N.S., Martinez A., Vicini F., Stromberg J. The histology or radiation therapy effect on prostate adenocarcinoma as assessed by needle biopsy after brachytherapy boost. Correlation with biochemical failure. Am J Clin Pathol. 110:1998;765-775.
30. Movsas B., Chapman J.D., Horwitz E.M., Pinover W.H., Greenberg R.E., Hanlon A.L., Iyer R., Hanks G.E. Hypoxic regions exist in human prostate carcinoma. Urology. 53:1999;11-18.
31. Fleshner N.E., O'Sullivan M., Fair W.R. Prevalence and predictors of a positive repeat transrectal ultrasound guided needle biopsy of the prostate. J Urol. 158:1997;505-508.
32. Naughton C.K., Smith D.S., Humphrey P.A., Catalona W.J., Keetch D.W. Clinical and pathologic tumor characteristics of prostate cancer as a function of the number of biopsy cores A retrospective study . Urology. 52:1998;808-813.
33. Rabbani F., Stroumbakis N., Kava B.R., Cookson M.S., Fair W.R. Incidence and clinical significance of false-negative sextant prostate biopsies. J Urol. 159:1998;1247-1259.
34. Norberg M., Egevad L., Holmberg L., Sparen P., Norlen B.J., Busch C. The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. Urology. 50:1997;562-566.
35. Epstein J.I., Walsh P.C., Sauvageot J., Carter H.B. Use of repeat sextant and transition zone biopsies for assessing extent of prostate cancer. J Urol. 158:1997;1886-1890.
36. Svetec D., McCabe K., Peretsman S., Klein E., Levin H., Optenberg S., Thompson I. Prostate rebiopsy is a poor surrogate of treatment efficacy in localized prostate cancer. J Urol. 159:1998;1606-1608.
37. Wiatrowski B.A., Robertson S., Crook J.M. Measures of proliferative activity in prostatic adenocarcinoma. J Urol Pathol. 6:1997;131-138.
38. Ljung G., Egevad L., Norberg M., de la Torre M., Holmberg L., Busch C., Nilsson S. Assessment of proliferation indicators in residual prostatic adenocarcinoma cells after radical external beam radiotherapy. The Prostate. 29:1996;303-310.
39. Pilepich M.V., Krall J.M., Al-Sarraf M., John M.J., Doggett R.L.S., Sause W.T., Lawton C.A., Abrams R.A., Rotman M., Rubin P., Shipley W.U., Grignon D., Caplan R., Cox J.D. Androgen deprivation with radiation therapy compared with radiation therapy alone for locally advanced prostatic carcinoma A randomized comparative trial of the Radiation Therapy Oncology Group . Urology. 45:1995;616-623.
40. Pilepich M.V., Winter K., Russell A.H., Sause W., Rubin P., Byhardt R., Machtay M., Grignon M. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation before and during radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 4215:1998;105A.
41. Laverdière J., Gomez J., Cusan L., Suburu E., Diamond P., Lemay M., Candas B., Fortin A., Labrie F. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys. 37:1997;247-252.